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Abstract
Objective Our objective was to assess healthcare resource utilization (HRU) and costs among patients with major depressive 
disorder (MDD) with and without treatment-resistant depression (TRD) and those without MDD in US Integrated Delivery 
Networks (IDNs).
Methods This was a retrospective matched-cohort study. The Optum© Integrated Claims Electronic Health Record de-
identified database was used to identify adult patients with TRD (January 2011–June 2017) across US IDNs. TRD patients 
were propensity score matched 1:1 with non-TRD MDD and non-MDD patients on demographics. Rates of HRU and costs 
were compared up to 2 years following the first antidepressant pharmacy claim (or randomly imputed date for non-MDD 
patients) using negative binomial and ordinary least squares regressions, respectively, with 95% confidence intervals (CIs) 
from nonparametric bootstraps (costs only) adjusted for baseline comorbidity index and costs.
Results All 1582 TRD patients were matched to non-TRD MDD and non-MDD patients and evaluated. TRD patients were 
on average 46 years old, and 67% were female. Mean duration of observation was 20.1, 19.6, and 17.9 months in the TRD, 
non-TRD MDD, and non-MDD cohorts, respectively. Patients with TRD had significantly higher rates of HRU than did 
non-TRD MDD patients (inpatient visits 0.35 vs. 0.16 per patient per year [PPPY]; adjusted incidence rate ratio [IRR] 2.04 
[95% CI 1.74–2.39]) and non-MDD patients (0.35 vs. 0.09 PPPY, adjusted IRR 3.05 [95% CI 2.54–3.66]). TRD patients 
incurred significantly higher costs PPPY than did non-TRD MDD patients ($US25,807 vs. 13,701, adjusted cost difference 
$US9479 [95% CI 7071–11,621]) and non-MDD patients ($US25,807 vs. 8500, adjusted cost difference $US11,433 [95% 
CI 8668–13,876]).
Conclusions HRU and costs associated with TRD are significant in US IDNs.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-019-0154-z) contains 
supplementary material, which is available to authorized users.
 * Dominic Pilon 
 dominic.pilon@analysisgroup.com
Extended author information available on the last page of the article
Key Points for Decision Makers 
Patients with major depressive disorder (MDD) and 
treatment-resistant depression (TRD) had higher 
healthcare resource utilization (HRU) and costs than did 
patients with MDD who were not resistant to treatment 
and those without MDD in US Integrated Delivery Net-
works (IDNs).
Patients with TRD had longer durations of antidepres-
sant therapies and greater variation in antidepressants; 
effective treatment strategies are urgently needed for this 
patient population.
The burden of TRD was mainly driven by medical-
related HRU and costs.
1 Introduction
Major depressive disorder (MDD) is a debilitating psychi-
atric disorder characterized by a loss of interest in previ-
ously enjoyable activities, chronic depression, and suicidal 
ideations [1]. MDD is one of the most prevalent behavioral 
health disorders in the United States (US) [2, 3], represent-
ing 6.7% (16.2 million adults) of the overall population [2]. 
The economic burden associated with MDD was estimated 
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at $US210.5 billion in 2010, with 45–47% of this burden 
attributed to direct healthcare costs and 48–50% due to 
workplace costs [4].
Antidepressant therapy represents the standard of care 
for patients with MDD; however, a considerable portion of 
patients (approximately 30%) develop treatment-resistant 
depression (TRD) [5], which is commonly defined as the 
failure to respond to at least two different antidepressants 
that are of adequate dose and duration [6, 7]. Although the 
health and economic burdens associated with MDD are 
considerable, recent studies have shown that patients with 
TRD experience an economic burden that is typically two-
to-threefold higher than patients who respond to treatment 
[8, 9]. A recent study examining direct healthcare costs asso-
ciated with TRD found that TRD patients had greater health-
care resource utilization (HRU) that resulted in considerably 
higher direct costs per patient per year (TRD $US17,261; 
non-TRD MDD $US9790; non-MDD $US4781) [8].
Modification of therapeutic approaches with each failed 
response requires TRD patients to seek ongoing care from 
healthcare providers across multiple settings [6, 10, 11]. 
However, fragmented care resulting from the lack of coor-
dination among different healthcare providers and organiza-
tions can interfere with the continuity of measurement-based 
care required to treat these patients [12, 13]. To overcome 
this challenge, collaborative care models such as integrated 
delivery networks (IDNs) have been proposed [11, 14]. 
Despite variations in the structure of IDNs, they are broadly 
defined as healthcare organizations that consist of multi-
ple physicians, hospitals, and other sources of patient care 
[15–18]. IDNs are increasingly recognized for their capacity 
to provide quality care across a continuum of settings (e.g., 
hospitals, health clinics, community health centers) within 
a single system [11, 19–21].
As organizations dedicated to coordinated patient care, 
IDNs typically assume financial accountability for patient 
outcomes, which is often associated with increased effi-
ciency and reduced healthcare costs [11]. Although care in 
IDNs is expected to decrease costs, conclusive evidence is 
lacking [15]. IDNs are commonly discussed within the con-
text of improved quality of care [22], yet evidence regard-
ing the costs among MDD and TRD patients treated within 
US IDNs is sparse. The limited number of reports assess-
ing behavioral health services in collaborative care models 
[15, 23, 24] have focused on heterogeneous populations of 
depressed patients who often have other comorbidities. As a 
result, these reports may not accurately capture the costs of 
care among TRD and non-TRD MDD patients. Therefore, 
this study was conducted to describe the HRU and costs 
among three cohorts of patients—those with TRD, those 
with non-TRD MDD, and those with no evidence of MDD—
who were treated within IDNs in the US.
2  Methods
2.1  Data Source
Optum Integrated Claims Electronic Health Records 
(EHRs) from 1 January 2011 to 30 June 2017 was used 
for this study. This database included information on > 10 
million individuals insured by UnitedHealth Group with 
their adjudicated claims linked to Humedica’s EHR. Data 
were de-identified and compliant with the requirements 
outlined in the Health Insurance Portability and Account-
ability Act.
2.2  Study Design
This retrospective matched-cohort study comprised three 
mutually exclusive TRD, non-TRD MDD, and non-MDD 
cohorts. The first antidepressant pharmacy claim (on or 
after 1 July 2011 for TRD and non-TRD MDD patients, 
and randomly imputed dates on or after 1 July 2011 for 
non-MDD patients) was defined as the index date. Patient 
characteristics were evaluated in the 6 months that pre-
ceded the index date (baseline period), and study out-
comes (treatment patterns, HRU, and costs) were evalu-
ated from the index date up to 2 years post-index date, 
the end of continuous enrollment in a health insurance 
plan, or end of data availability (30 June 2017), whichever 
occurred first. Since the average time to become TRD was 
reported to be 1.3 years [6], a 2-year period was used to 
allow MDD patients the opportunity to be classified as 
TRD.
Patients with one or more visits to an IDN were con-
sidered IDN patients. Once patients were seen in an IDN, 
they remain flagged as IDN patients even if they later 
received care in a non-IDN setting. The IDN indicator was 
not determined at the patient level and was therefore not 
time or visit specific. Although a consensus definition of an 
IDN is lacking [15], an IDN was defined as a coordinated 
hospital inpatient and outpatient system that offers health-
care services in a defined geographic area in the Optum 
database. Multiple coordinated hospitals or IDNs could be 
included. IDNs that were included are primarily hospital 
based in Optum, but they provide more comprehensive ser-
vices than solely inpatient care. Moreover, Optum defined 
an IDN as a provider network-level variable; providers 
self-identified whether they were IDNs and were required 
to have inpatient data to support their status as IDNs. In 
this study, 80.1% of the MDD cohort were associated with 
an IDN, whereas 75.7% were associated in the non-MDD 
cohort (Tables S1–2).
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2.3  Study Cohorts
Patients with TRD (TRD cohort) were compared with 
two control cohorts: patients with MDD who did not have 
TRD (non-TRD MDD cohort) and patients without MDD 
(non-MDD cohort). Patients in both control cohorts were 
propensity score (PS) matched 1:1 with patients in the 
TRD cohort.
To be included in both the TRD and the non-TRD MDD 
cohorts, patients were required to meet the following cri-
teria: (1) one or more diagnoses for MDD (International 
Classification of Diseases, Ninth Edition, Clinical Modifica-
tion [ICD-9-CM]: 296.2x [MDD – single episode], 296.3x 
[MDD – recurrent episode]; ICD, Tenth Edition, CM [ICD-
10-CM]: F32.x [excluding F32.8], F33.x [excluding F33.8]); 
(2) one or more claims for an antidepressant between 1 July 
2011 and 30 June 2017 (MDD diagnosis could occur before 
or after the first antidepressant pharmacy claim); (3) one or 
more diagnoses of depression (ICD-9-CM: 296.2x, 296.3x, 
300.4x, 311.x, 309.0x, or 309.1x; ICD-10-CM: F32.x, 
F33.x, F34.1, or F43.21) during the baseline or observation 
period. Both the baseline and follow-up periods were used to 
identify patients with depression due to the episodic nature 
of the disease [25].
2.3.1  Treatment‑Resistant Depression (TRD) Cohort
In the TRD cohort, a pharmacy claims-based algorithm was 
used to identify MDD patients who were likely to have TRD 
within 2 years after the index date (i.e., follow-up). MDD 
patients were considered likely to have TRD if their MDD 
did not respond to two antidepressant treatment regimens, 
including augmentation therapy with an anticonvulsant, 
anxiolytic, antipsychotic, lithium, psychostimulant, or thy-
roid hormone medication, with adequate dose and duration 
(> 6 weeks) as per the American Psychiatric Association 
guidelines [7]. Failure of a treatment regimen was defined 
as a switch of antidepressant (i.e., < 180 days after the end 
of the previous treatment), the addition of an antidepressant, 
or the initiation of an augmentation therapy. The initiation 
of the third treatment regimen had to occur > 6 weeks after 
the start of the first antidepressant treatment.
2.3.2  Non‑TRD Major Depressive Disorder (MDD) Cohort
Patients in the non-TRD MDD cohort included MDD 
patients who did not meet the criteria for TRD, as previ-
ously defined, within 2 years of the index date.
2.3.3  Non‑MDD Cohort
Patients in the non-MDD cohort consisted of a randomly 
selected sample of patients without MDD (ICD-9-CM: 
296.2x, 296.3x; ICD-10-CM: F32.x, F33.x [excluding 
F33.8]) from 1 January 2011 to 30 June 2017. Since a retro-
spective matched-cohort study design was used, the random 
selection of 500,000 non-MDD patients was considered suf-
ficient to provide a pool of controls eligible for matching.
2.3.4  All Cohorts
All patients included in this study were required to meet 
the following conditions: (1) no diagnosis for specific psy-
chiatric comorbidities (i.e., psychosis [ICD-9-CM: 298.xx; 
ICD-10-CM: F23.x, F25.x, F44.89], schizophrenia [ICD-
9-CM: 295.xx; ICD-10-CM: F20.x, F25.x], bipolar disor-
der/manic depression [ICD-9-CM: 296.0x, 296.1x, 296.4x, 
296.5x, 296.6x, 296.7x, 296.8x; ICD-10-CM: F30.x, F31.x], 
dementia [ICD-9-CM: 290.xx, 294.1x; ICD-10-CM: F01.x, 
F02.x, F03.x]) between 1 January 2011 and 30 June 2017; 
(2) ≥ 18 years at the index date; (3) ≥ 6 months of continuous 
enrollment in a health insurance plan before and after the 
index date; (4) no antidepressant claims during the baseline 
period.
2.4  Study Measures
Baseline characteristics included demographics, physical 
and mental comorbidities, medication use, HRU, and costs 
were used to assess the distribution of the TRD, non-TRD, 
and non-MDD cohorts.
For each cohort, the proportion of patients receiving anti-
depressant medications during the observation period was 
reported. Duration of antidepressant therapy was also pre-
sented and defined as the number of days with medication 
available between the first antidepressant claim (i.e., index 
date) and the last day of supply of antidepressant with no 
gaps > 14 days (gaps were excluded in duration of therapy).
HRU and costs were categorized as all-cause, behavioral 
health-related, depression-related, and suicide-related. For 
each category, HRU and costs were divided into inpatient 
visits, inpatient days, emergency department (ED) visits, 
outpatient visits, and other visits. Behavioral health-related 
medical HRU and costs (including depression-related but 
not suicide-related costs) were identified using primary 
or secondary ICD-9-CM diagnostic codes 290.xx–319.
xx and ICD-10-CM diagnostic codes F01.xxx–F99.xxx. 
Psychiatric pharmacy costs included the following classes 
of agents: anxiolytics, antidepressants, anticonvulsants/
mood stabilizers, antipsychotics, and other mood stabiliz-
ers (e.g., lithium). Depression-related HRU and costs were 
122 D. Pilon et al.
identified using primary or secondary ICD-9-CM diagnos-
tic codes 296.2x, 296.3x, 300.4x, 309.0x, 309.1x, 311.xx 
and ICD-10-CM diagnostic codes F32.x, F33.x, F34.1, or 
F43.21. Antidepressant pharmacy costs included the follow-
ing classes of agents, selective serotonin reuptake inhibi-
tors (SSRIs), norepinephrine-dopamine reuptake inhibitors 
(NDRIs), serotonin-norepinephrine reuptake inhibitors 
(SNRIs), serotonin modulators (i.e., nefazodone, trazo-
done, vilazodone, venlafaxine), tricyclics and tetracyclics, 
norepinephrine-serotonin modulators, monoamine oxidase 
inhibitors (MAOIs), and other (i.e., olanzapine-fluoxetine). 
Suicide-related HRU and costs were defined using primary 
or secondary ICD-9-CM diagnostic codes E95x or V62.84 
and ICD-10-CM diagnostic codes T14.91x, X71.x-X83.x, 
T36.x- T65.x with a suffix of ‘2’ indicating ‘intentional self-
harm’, T71.x with a suffix of ‘2’ indicating ‘intentional self-
harm’ or R45.851.
2.5  Statistical Analysis
Patients with TRD were matched 1:1 to non-TRD MDD 
and non-MDD patients using PS defined as the conditional 
probability of having TRD based on observable character-
istics [26, 27]. The PS across patients were classified into 
strata, each containing an equal proportion of patients (5%). 
One TRD patient was matched to one non-TRD MDD and 
one non-MDD patient within the same stratum. The logistic 
regression model was used to estimate the PS, where hav-
ing TRD (yes/no) was the binary dependent variable and 
patient characteristics were the predictors and included age, 
sex, race, year of the index date, geographical region, and 
type of healthcare plan. Baseline patient characteristics were 
compared using standardized differences; a covariate with 
a standardized difference < 10% was considered well-bal-
anced [26]. Rates of HRU were compared between matched 
cohorts using multivariable negative binomial regression 
(i.e., incidence rate ratios [IRRs]). Costs were expressed as 
per patient per year (PPPY) in $US, year 2017 values, using 
the Consumer Price Index for Medical care using means, 
standard deviations (SDs), and medians, and adjusted cost 
differences were calculated using multivariable ordinary 
least squares regression with 95% confidence intervals (CIs) 
and p-values obtained from nonparametric bootstraps with 
499 replications. To account for censoring in the cost data, 
a phase-based approach has been recommended in studying 
cumulative costs [28]. Specifically, mean costs per patient 
per month (PPPM) in the 6 months before and up to 2 years 
after the index date and stratified by 1-month periods were 
calculated as a sensitivity analysis. Since the matching was 
limited to demographic variables, baseline Quan-Charlson 
comorbidity index (Quan-CCI) [29] and all-cause health-
care costs were adjusted for in the multivariable models 
due to the remaining imbalances observed after matching. 
Given that TRD is complex, with multifactorial causes and 
effects with respect to other comorbidities, minimally match-
ing on and controlling for potential confounders to avoid 
conditioning on mediators was deemed appropriate in this 
context. For the parameter estimates, standard errors, and 
Akaike information criterion from the regression models, 
see Tables S3–7.
3  Results
3.1  Baseline Demographic and Clinical 
Characteristics
Among 12,730 treated patients with MDD, 1582 (12%) met 
the criteria for TRD (Table S1). A total of 63,828 patients 
without MDD who met the inclusion criteria were identified 
(Table S2). Before matching, TRD patients were younger 
than non-TRD MDD and non-MDD patients (Table S8). 
After matching, cohorts were well-balanced (standardized 
difference < 10%) on demographic factors (Table 1). TRD 
patients were more likely to have other behavioral health-
related medication use during the baseline period, even 
after matching. See Figs. S1–S2 for PS distributions. The 
mean duration of the observation period was 20.1, 19.6, and 
17.9 months in the TRD, non-TRD MDD, and non-MDD 
cohorts, respectively.
3.2  Treatment Patterns
Patients with TRD used a greater variety of antidepres-
sants than did patients in the other cohorts. In the TRD and 
non-TRD MDD cohorts, the three most frequently used 
antidepressants included SSRIs (89 vs. 81%), NDRIs (47 
vs. 22%), and SNRIs (45 vs. 16%; Fig. 1). The use of anti-
depressants was low in the non-MDD cohort (SSRIs 8%, 
NDRIs 2%, and SNRIs 2%). The duration of antidepressant 
therapy was longer among TRD patients than among non-
TRD MDD and non-MDD patients (Table S9).
3.3  Healthcare Resource Utilization (HRU) and Costs
Patients with TRD had higher rates of HRU during the 
observation period than did the non-TRD MDD and non-
MDD patients (Fig. 2). TRD patients had 2.04 (95% CI 
1.74–2.39) and 3.05 (95% CI 2.54–3.66) times the rate of 
inpatient visits for non-TRD MDD and non-MDD patients, 
respectively. All-cause inpatient length of stay was higher 
for TRD patients (3.19 days) than for non-TRD (1.04 days) 
and non-MDD (0.78  days) patients (adjusted IRR 2.98 
[95% CI 2.34–3.81] and 2.43 [95% CI 1.85–3.20], respec-
tively). Similarly, TRD patients had higher rates of behav-
ioral health-related HRU (e.g., 2.61 [95% CI 2.23–3.06] 
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Table 1  Baseline characteristics, healthcare resource utilization, and all-cause healthcare costs evaluated 6 months prior to the index date
Variables Matched  populationa
TRD cohort Non-TRD MDD cohort Std. diff.b (%) Non-MDD control cohort Std. diff.b (%)
N = 1582 N = 1582 N = 1582
Age at index date, years 45.6 ± 16.6 [45] 45.4 ± 16.7 [44] 0.7 44.9 ± 16.8 [44] 4.1
Female 1052 (66.5) 1067 (67.4) 2.0 1088 (68.8) 5.0
Race
 White 1345 (85.0) 1339 (84.6) 1.1 1313 (83.0) 5.4
 Black 68 (4.3) 69 (4.4) 0.3 58 (3.7) 3.2
 Asian 16 (1.0) 15 (0.9) 0.6 15 (0.9) 0.6
 Hispanic 51 (3.2) 68 (4.3) 5.7 76 (4.8) 8.1
 Other/unknown 102 (6.4) 91 (5.8) 2.9 120 (7.6) 4.5
Year of index  datec
 2011 215 (13.6) 203 (12.8) 2.2 224 (14.2) 1.6
 2012 266 (16.8) 256 (16.2) 1.7 273 (17.3) 1.2
 2013 260 (16.4) 262 (16.6) 0.3 286 (18.1) 4.4
 2014 250 (15.8) 243 (15.4) 1.2 259 (16.4) 1.6
 2015 292 (18.5) 294 (18.6) 0.3 291 (18.4) 0.2
 2016 246 (15.5) 274 (17.3) 4.8 249 (15.7) 0.5
 2017 53 (3.4) 50 (3.2) 1.1 0 (0.0) 25.9
Geographical  regiond
 Northeast 160 (10.1) 163 (10.3) 0.6 163 (10.3) 0.6
 Midwest 792 (50.1) 768 (48.5) 3.0 807 (51.0) 1.9
 South 396 (25.0) 419 (26.5) 3.3 378 (23.9) 2.6
 West 191 (12.1) 178 (11.3) 2.6 185 (11.7) 1.2
 Unknown 43 (2.7) 54 (3.4) 4.0 49 (3.1) 2.3
Type of healthcare plan
 Medicare 283 (17.9) 259 (16.4) 4.0 254 (16.1) 4.9
 Commercial 1299 (82.1) 1323 (83.6) 4.1 1328 (83.9) 5.0
 Preferred provider organization 78 (4.9) 85 (5.4) 2.0 84 (5.3) 1.7
 Point of service plan 907 (57.3) 908 (57.4) 0.1 955 (60.4) 6.3
 Health management organization 189 (11.9) 187 (11.8) 0.4 176 (11.1) 2.6
 Exclusive provider organization 84 (5.3) 93 (5.9) 2.5 71 (4.5) 3.8
 Other healthcare plan 41 (2.6) 50 (3.2) 3.4 42 (2.7) 0.4
Quan-CCI [29] 0.6 ± 1.3 [0] 0.5 ± 1.1 [0] 12.1 0.3 ± 0.9 [0] 29.0
Number of unique mental health 
diagnoses
1.2 ± 1.6 [1] 0.9 ± 1.3 [0] 20.8 0.2 ± 0.5 [1] 84.3
Other mental health-related medi-
cation use [42, 43]e
614 (38.8) 343 (21.7) 35.2 152 (9.6) 62.4
Top five most frequent physical comorbidities [44]f
 Hypertension 405 (25.6) 338 (21.4) 9.9 243 (15.4) 24.6
 Diabetes 196 (12.4) 147 (9.3) 9.9 92 (5.8) 22.5
 Chronic pulmonary disease 167 (10.6) 157 (9.9) 2.1 94 (5.9) 16.6
 Obesity 127 (8.0) 128 (8.1) 0.2 78 (4.9) 12.5
 Hypothyroidism 140 (8.8) 121 (7.6) 4.4 100 (6.3) 9.5
Top five most frequent mental  comorbiditiesg
 Depressionh 556 (35.1) 478 (30.2) 10.3 37 (2.3) 76.7
 Anxiety disorders 345 (21.8) 245 (15.5) 15.9 70 (4.4) 49.1
 Sleep–wake disorders 220 (13.9) 154 (9.7) 12.8 65 (4.1) 33.3
 Substance-related and addictive 
disorders
188 (11.9) 116 (7.3) 15.3 55 (3.5) 30.9
124 D. Pilon et al.
and 17.44 [95% CI 11.62–26.16] times the rate of inpatient 
visits for TRD patients vs. non-TRD MDD and non-MDD 
patients, respectively); the rate of depression- and suicide-
related inpatient visits was 2.48 (95% CI 1.98–3.11) and 
3.26 (95% CI 2.28–4.68), respectively, times higher for the 
TRD than for the non-TRD MDD patients (Table S10).
During the baseline period, the mean all-cause healthcare 
cost PPPY was $US21,872, $US13,696, and $US7160 for 
TRD, non-TRD MDD, and non-MDD patients, respectively 
(Table 1). For the TRD and non-TRD MDD cohorts, all-
cause medical costs were $US19,802 and 12,357, respec-
tively, which accounted for > 90% of all-cause healthcare 
costs. During the follow-up period, the unadjusted cost 
differences PPPY illustrated that all-cause healthcare costs 
for the TRD cohort were 88% and 304% higher than for 
the non-TRD MDD and non-MDD cohorts ($US25,807 
[TRD] vs. 13,701 [non-TRD MDD] or 8500 [non-MDD]; 
Table 2). After adjusting for baseline Quan-CCI and all-
cause healthcare costs, TRD patients had significantly higher 
PPPY all-cause healthcare costs than did non-TRD MDD 
and non-MDD patients ($US9479 [95% CI 7071–11,621] 
more than the non-TRD MDD cohort and $US11,433 [95% 
CI 8668–13,876] more than the non-MDD cohort; Fig. 3). 
Similarly, TRD patients had the highest all-cause inpatient 
costs ($US3805 [95% CI 2289–5268] more than the non-
TRD MDD cohort and $US4199 [95% CI 2566–5484] more 
than the non-MDD cohort), which were the main drivers of 
the adjusted cost difference (Table 2). Additionally, mean 
Table 1  (continued)
Variables Matched  populationa
TRD cohort Non-TRD MDD cohort Std. diff.b (%) Non-MDD control cohort Std. diff.b (%)
N = 1582 N = 1582 N = 1582
 Other conditions that may be a 
focus of clinical attention
121 (7.6) 110 (7.0) 2.7 65 (4.1) 14.9
Had ≥ 1 healthcare visit/service
 Inpatient 217 (13.7) 144 (9.1) 14.3 57 (3.6) 35.0
 ED 203 (12.8) 178 (11.3) 4.8 112 (7.1) 18.9
 Outpatient 1398 (88.4) 1342 (84.8) 9.8 1180 (74.6) 30.3
 Other 366 (23.1) 306 (19.3) 9.2 193 (12.2) 27.8
All-cause healthcare costs ($US, 
year 2017 values)
21,872 ± 61,869 [4937] 13,696 ± 44,271 [2643] 15.2 7160 ± 24,755 [1350] 31.2
 Medical costs 19,802 ± 60,601 [3363] 12,357 ± 43,421 [1740] 14.1 5918 ± 23,754 [868] 30.2
 Pharmacy costs 2070 ± 6719 [420] 1339 ± 4201 [230] 13.0 1242 ± 5943 [105] 13.1
Data are presented as n (%) or mean ± standard deviation [median] unless otherwise indicated
ED emergency department, ICD-x-CM International Classification of Diseases, xth edition, Clinical Modification, MDD major depressive disor-
der, Quan-CCI Quan-Charlson comorbidity index, SD standard deviation, Std. diff. standardized difference, TRD treatment-resistant depression
a Patients were matched on propensity score (the probability of being in the TRD cohort vs. the non-TRD MDD or non-MDD cohort), modelled 
using a logistic regression model adjusted for categorical age, sex, race, year of the index date, geographical region, and type of healthcare plan
b For continuous variables, the std. diff. was calculated by dividing the absolute difference in means of the control and the TRD cohorts by the 
pooled SD of both groups. The pooled SD is the square root of the average of the squared SDs. For dichotomous variables, the std. diff. was cal-
culated using the following equation, where P is the respective proportion of participants in each group: (PTRD − Pcontrol)/√[(PTRD(1 − PTR
D) + Pcontrol(1 − Pcontrol))/2]
c For TRD and non-TRD MDD patients, the index date was defined as the date of the first prescription fill for an antidepressant. For non-MDD 
patients, the index date was randomly generated
d Based on US census regions (http://www2.censu s.gov/geo/pdfs/maps-data/maps/refer ence/us_regdi v.pdf)
e Includes anxiolytics, anticonvulsants/mood stabilizers, antipsychotics, psychostimulants, thyroid hormone (T3), and lithium. Agents were 
grouped according to their generic name
f The top five most frequent Elixhauser comorbidities identified in the TRD cohort were reported
g The top five most frequent mental disorders identified in the TRD cohort were reported
h Depression diagnoses included the following diagnoses ICD-9-CM: 296.2x (MDD—single episode), 296.3x (MDD—recurrent episode), 
300.4x (dysthymic disorder), 309.0x (adjustment disorder with depressed mood), 309.1x (prolonged depressive reaction), and 311.x (depressive 
disorder, not elsewhere classified) or ICD-10-CM: F32x (MDD—single episode), F33x (MDD—recurrent episode), F341 (dysthymic disorder) 
and F4321 (adjustment disorder with depressed mood). All patients had to have a diagnosis of MDD during the study period, but only a portion 
had an MDD diagnosis during the baseline period
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Fig. 1  Medication treatment patterns during the observation period 
among TRD, non-TRD MDD, and non-MDD cohorts. MDD major 
depressive disorder, NDRIs norepinephrine-dopamine reuptake 
inhibitors, SNRIs serotonin-norepinephrine reuptake inhibitors, SSRIs 









Inpatient visits 0.35 0.16 2.04 (1.74 - 2.39) <0.001*
Number of days 3.19 1.04 2.98 (2.34 - 3.81) <0.001*
ED visits 0.84 0.59 1.40 (1.14 - 1.71) 0.001*
Outpatient visits 21.97 14.08 1.50 (1.42 - 1.59) <0.001*
Other visits 2.73 1.87 1.27 (1.08 - 1.49) 0.004*
D cohort versus non
(b)
(a)
D cohort versus non-MDD cohort
Healthcare resource 
utilization, PPPY TRD Non-MDD Adjusted IRR(95% CI) P-value
Inpatient visits 0.35 0.09 3.05 (2.54 - 3.66) <0.001*
Number of days 3.19 0.78 2.43 (1.85 - 3.20) <0.001*
ED visits 0.84 0.42 1.86 (1.50 - 2.31) <0.001*
Outpatient visits 21.97 8.16 2.66 (2.49 - 2.84) <0.001*
Other visits 2.73 0.91 2.29 (1.93 - 2.73) <0.001*
0.0 1.0 2.0 3.0 4.0
Higher rate among TRD cohort versus control cohort
0.0 1.0 2.0 3.0 4.0
Higher rate among TRD cohort versus control cohort
Fig. 2  Healthcare resource utilization measured from the index date 
up to 2  years post-index  datea. aMultivariable negative binomial 
regression included baseline all-cause healthcare costs and Quan-
CCI. *Significant at the 5% level. CI confidence interval, ED emer-
gency department, HRU healthcare resource utilization, IRR inci-
dence rate ratio, MDD major depressive disorder, PPPY per patient 
per year, Quan-CCI Quan–Charlson comorbidity index, TRD treat-
ment-resistant depression
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costs PPPM in the 6 months before and up to 2 years after 
the index date and stratified by a 1-month period are pre-
sented in Fig. S3. Although there was some variability, mean 
costs PPPM were on average higher in TRD than non-TRD 
MDD cohorts ($US1762–2863 vs. 839–1757) each month.
4  Discussion
The results of this retrospective matched-cohort analysis 
demonstrated that patients with TRD in IDN settings across 
the US had a longer duration of antidepressant therapy and 
a greater number of unique antidepressant medications than 
patients with MDD that were not resistant to treatment and 
than patients without MDD. From baseline to follow-up, 
TRD patients had higher costs and rates of HRU than did 
non-TRD MDD and non-MDD patients. All-cause medical 
and pharmacy costs were also higher, on average, among 
TRD patients. During the baseline period, TRD patients had 
higher rates of HRU, particularly behavioral health-related 
HRU than did non-TRD MDD patients and non-MDD 
patients. TRD patients also had higher healthcare costs, with 
inpatient costs serving as the main driver of this increased 
adjusted cost difference.
In this study, healthcare costs were considerably high 
and contrary to expectations that IDNs are associated with 
lower costs [11, 15, 30]. Instead, the higher HRU and costs 
among TRD patients relative to non-TRD MDD or non-
MDD patients in this study aligned with previous com-
mercial claims-based studies of patients treated in non-IDN 
settings [6, 8, 9, 31, 32]. A recent study, by Amos et al. 
[8], evaluated HRU and costs among commercially insured 
TRD patients using a similar study design as the present 
study, which allows for indirect comparisons. Results of 
that analysis demonstrated that the rates of HRU for TRD 
patients were higher than rates for patients in the non-TRD 
MDD and non-MDD cohorts (2.0 and 4.7 times the rate 
of inpatient visits versus the non-TRD MDD and non-
MDD cohorts, respectively; all p < 0.001). As in our study, 
TRD patients also incurred significantly higher healthcare 
costs PPPY than non-TRD MDD patients and non-MDD 
patients ($US6709 more than the non-TRD MDD cohort and 
$US9917 more than the non-MDD cohort; all p < 0.001). 
Interestingly, the adjusted all-cause healthcare cost differ-
ence for TRD versus non-TRD MDD patients in this study 
were higher than the cost difference reported by Amos et al. 
[8] ($US9479 vs. 6709). Given our IDN definition, the 
difference in costs may result from linking outpatient and 
inpatient institutions, which can increase the costs of both 
outpatient and inpatient care, as suggested by previous litera-
ture on IDNs [33]. Another potential explanation to account 
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by healthcare providers in IDNs resulting in an increased 
awareness of patients’ worsening symptoms, which would 
require additional care and ultimately contribute to greater 
HRU and costs.
To the best of our knowledge, this is the first study to 
highlight treatment patterns, HRU, and costs associated 
with TRD, non-TRD MDD, and non-MDD patients treated 
in US IDNs. As a result, direct comparisons with other 
studies are a challenge because of the differences in study 
parameters and patient populations evaluated. However, one 
study published in 2003, by Liu et al. [34], examined the cost 
effectiveness of collaborative care for veterans with MDD 
and reported an increase in costs associated with collabo-
rative care. As expected, their explanation for the higher 
costs were the greater resources needed to adequately treat 
MDD patients. Despite methodological differences between 
that study and the present work, it is reasonable to conclude 
that the high HRU and costs pertain to the greater needs of 
the TRD patient population. The HRU and costs among the 
cohorts in this study provide a useful benchmark to help 
direct efforts in reducing the health and economic burdens 
associated with MDD, particularly TRD. Consequently, this 
study fills an important knowledge gap for IDN decision 
makers regarding real-world treatment patterns and cost dif-
ferences for TRD patients, which significantly contributes to 
the overall burden of MDD.
Although the results of this study do not support lower 
costs among TRD or non-TRD MDD patients treated in 
IDNs, it is possible that the true benefit of IDNs among 
these patient populations is in the quality of care received. 
Given the care coordination among providers across a 
continuum of settings, IDNs are particularly relevant for 
patients with behavioral health disorders [19, 35]. Sev-
eral studies have documented improved patient outcomes 
within IDNs for patients with depressive disorders [36–39]. 
For example, one study based on longitudinal data found 
that patients treated in highly integrated programs had 
greater improvement in self-reported physical health and 
mental health recovery assessed by their clinician [40]. 
Another study that compared outcomes among patients 
with depression who received collaborative care and those 
who received usual care found that collaborative care was 
associated with significant improvement in adherence to 
therapy (75 vs. 50%), patient perception of quality of care 
(93 vs. 75%), and patient-reported improvement in efficacy 
of antidepressant therapy (88 vs. 63%) [36]. The fact that 
several studies highlight improved quality of care among 
heterogeneous patient populations underscores the value of 
IDNs. It is possible that the higher quality of care may result 
in reduced costs long term; however, additional studies are 
warranted to explore this possibility among TRD, non-TRD 
MDD, and non-MDD patients treated across different types 
of IDNs versus non-IDN settings.
Fig. 3  All-cause healthcare costs per patient per year measured from 
the index date up to 2  years post-index  datea,b. aMultivariable ordi-
nary least squares regression included baseline all-cause healthcare 
costs and Quan-CCI; bTotal costs are presented in the black text. 
Medical and pharmacy costs are presented in the green and blue texts, 
respectively. *Significant at the 5% level. CI confidence interval, ED 
emergency department, MDD major depressive disorder, PPPY per 
patient per year, Quan-CCI Quan-Charlson comorbidity index, TRD 
treatment-resistant depression
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4.1  Limitations
This study should be interpreted within the context of cer-
tain limitations. First, the treatment failure algorithm used 
to identify patients with TRD relied solely on pharmacy 
claims; clinical considerations to specifically assess treat-
ment failure, response, and remission could not be incor-
porated. Furthermore, the algorithm used to identify the 
TRD study population may not be representative of all 
TRD patients as only patients with an adequate dose and 
duration of antidepressant were selected. Second, because 
patients with a single IDN visit were included in the analy-
sis, it is possible that some of the patients evaluated did 
not experience the care associated with multiple visits to an 
IDN. Additionally, once patients are seen in an IDN, they 
remain flagged as IDN patients even if they later receive 
care in a non-IDN setting. Although this may prevent us 
from accurately identifying patients who are truly seen in 
an IDN setting, we hypothesized that patients seen in an 
IDN typically prefer to continue their care within the same 
IDN in which they were initially seen based on available 
literature on patient experience in IDNs [33, 41]. Third, PS 
matching based on demographic variables was conducted to 
minimize the confounding between the TRD and non-TRD 
MDD or non-MDD cohorts. However, since imbalances 
remained after matching, we further adjusted for baseline 
Quan-CCI and all-cause healthcare costs. Although PS 
matching and adjustment techniques were used to minimize 
the potential confounding, these comparisons may still be 
subject to residual confounding from unmeasured confound-
ers. Fourth, to evaluate baseline characteristics and study 
outcomes, a minimum of 6 months of continuous enrollment 
in a health insurance plan before and after the index date was 
imposed on the study population. However, patients who do 
not have ≥ 6 months of continuous enrollment before or after 
the index date may have differed in the continuity of care 
received. This may limit the generalizability of the HRU and 
cost burden reported in this study. Lastly, there is currently 
no industry standard to define an IDN [15]. In this study, 
an IDN was defined as a coordinated hospital inpatient and 
outpatient system offering healthcare services in a defined 
geographical region. Therefore, the results may not be gen-
eralizable to all US IDNs.
5  Conclusions
Patients with TRD who received care in IDNs had higher 
HRU and incremental costs than patients with MDD who 
were not resistant to treatment and those without MDD. 
The HRU and economic burden associated with TRD were 
substantial in the US IDN setting and was mainly driven by 
non-behavioral health-related HRU and costs.
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